VIVUS, Inc.

  • Solta Ready To Be Next Big Winner In $60 Billion Weight Loss Market

    By George Shrader - August 30, 2013 | Tickers: ARNA, NTRI, SLTM, VVUS, WTW

    With over 200 million overweight or obese Americans, the $60 billion weight loss market is an attractive space for investors looking for a company with a better mousetrap. Losing weight has been one of the most difficult challenges ever faced but now with the Solta Medical, Inc. (NASDAQ: SLTM), breakthrough losing weight is easier and light years faster than ever before. Solta makes it instantaneous and pain free with no more »

  • Will Orexigen's European Strategy Pay Off?

    By Spencer Osborne - August 20, 2013 | Tickers: ARNA, OREX, VVUS

    When people think of the anti-obesity space three companies typically come to mind.  Vivus (NASDAQ: VVUS), Arena Pharmaceuticals (NASDAQ: ARNA) and Orexigen Therapeutics (NASDAQ: OREX).  These three companies are at the new forefront of prescription anti-obesity medications.  The Vivus drug, Qsymia was the first to market last Fall.  Arena's Belviq this past June.  Meanwhile, Orexigen's Contrave is still in the midst of trials.  So why should the third more »

  • 3 Signs a Drug Will Fail

    By Brandy Betz - August 19, 2013 | Tickers: LLY, IPXL, VVUS

    Biotech and pharma investing often focuses on the potential approval and marketability of drugs. This can involve short-term investors trading on binary events or long-term investors weighing the marketability of several products to determine a company’s overall potential.

    A Food and Drug Administration approval doesn’t guarantee a product’s success. Some drugs are obviously heading out into a blockbuster market -- such as the all-oral hepatitis C treatments coming more »

  • New Weight Loss Treatments Could Boost Sales for These 3 Biotechs

    By Leo Sun - August 13, 2013 | Tickers: ARNA, OREX, VVUS

    Arena Pharmaceuticals (NASDAQ: ARNA) is a controversial stock among biotech investors. The bulls believe that increasing rates of global obesity will inevitably trigger more sales of its new weight loss drug, Belviq, which was approved by the FDA last June. However, the bears believe that lingering safety concerns regarding Belviq and the company’s insistence on combining the treatment with other medications could cause problems down the road.

    Over the more »

  • Qsymia Sales Run Adds Value to Arena Pharmaceuticals

    By Craig Keolanui - July 29, 2013 | Tickers: ARNA, ESALY.PK, VVUS

    Will the current success of Vivus (VVUS) with Qsymia open the door for obesity drugs and Arena Pharmaceutical's (ARNA) Belviq? Qsymia sales have more than doubled in the last five weeks going from weekly sales levels of around 4,000 prescriptions to over 9,000 for the second week in July. Despite some speculation regarding the possibility of double-counting mail order and retail prescriptions, there still seems to be more »

  • How You Should Play These Weight-Loss Drug Companies

    By Sherrie Stone - July 22, 2013 | Tickers: ARNA, OREX, VVUS

    The two weight-loss drug approvals in 2012 were the first in more than a decade. The excitement surrounding Arena Pharmaceuticals(NASDAQ: ARNA) Belviq and Vivus’ (NASDAQ: VVUS) Qsymia led to massive gains in the months prior to their FDA approvals. Since then, both companies' shares have fallen as dramatically as they rose, suggesting a reoccurring pattern of high hopes and cruel reality for weight-loss drug makers. Will a third weight-loss more »

  • What Should You Expect From Arena and Vivus?

    By Ishtiaq Ahmed - July 15, 2013 | Tickers: ARNA, VVUS

    The anti-obesity market is becoming interesting as Arena Pharmaceuticals (NASDAQ: ARNA) has launched its anti-obesity drug, Belviq.

    For a long time, Vivus (NASDAQ: VVUS) was operating as the only player in the anti-obesity market. However, the entry by Arena has changed the dynamics of the market, and we will now see two rivals going head-to-head for this large market in the U.S.

    How big is the market?

    Obesity has more »

  • 1 Biotech You Might Want to Explore: Right Now!

    By Brian Nichols - July 8, 2013 | Tickers: ARNA, GSK, VVUS

    After more than a year, Arena Pharmaceuticals(NASDAQ: ARNA) weight-loss drug Belviq has finally launched. Let's look at recent history to determine how successful the drug might be, in both the short and long terms. 

    A Tough Start for the First to Market

    VIVUS’ (NASDAQ: VVUS) Qsymia was first to market, having already been sold for half of the last year. However, sales have been less than encouraging, as more »

  • Should You Buy the Hype Surrounding This Product Launch?

    By Sherrie Stone - July 1, 2013 | Tickers: AMRN, ARIA, GALE, VVUS

    While the analysis of peak sales and potential patient populations may be appealing to most, it costs a great deal of money to launch a new product with success. In the case of Galena Biopharma (NASDAQ: GALE), the company doesn’t have the cash, but touts tremendous sales potential, so might the company succeed anyway?

    The reality of launching drugs in healthcare

    I would like to share with you something more »

  • Qsymia Just Won The Lotto

    By Mohsin Saeed - June 27, 2013 | Tickers: ARNA, OREX, VVUS

    After almost a decade, the FDA has once again started approving obesity drugs. Vivus’ (NASDAQ: VVUS) Qysmia and Arena’s (NASDAQ: ARNA) Belviq have received FDA approval and are already available in the market. Belviq has just received DEA clearance and is a late entrant into the market, though the drug is regarded as the safer option and is readily available from local pharmacies. Orexigen’s (NASDAQ: OREX) Contrave is more »

  • Weight Loss Drug Sweepstakes

    By Alexander Maxwell - June 26, 2013 | Tickers: ARNA, OREX, VVUS

    The weight-loss industry has been heating up quite a bit over the past few quarters.

    First investors were reminded of the struggle between Vivus (NASDAQ: VVUS), Arena Pharmaceuticals (NASDAQ: ARNA) and Orexigen Therapeutics (NASDAQ: OREX) to see which company could get their drug on the market first. Now, that Vivus has Qsymia on the market and Arena has Belviq on the market, it appears as though all of the companies more »

  • The Week's Biotech Winner and Loser

    By Brandy Betz - June 24, 2013 | Tickers: IDIX, PFE, SRPT, VVUS

    What’s the best way to choose the biotech winner and loser of the past week?

    The easiest route would involve the companies with the biggest share price movements. That would make Idenix (NASDAQ: IDIX) the obvious loser with its over 30% drop after the FDA requested additional preclinical safety information for a hepatitis C drug. But that movement came from volatility that arose despite the fact that this wasn more »

  • What to Expect From Arena Pharmaceuticals' Launch of Belviq

    By REZA GANJAVI - June 20, 2013 | Tickers: ARNA, VVUS

    After years of anticipation by doctors, patients, and investors, Belviq was finally launched last week for treatment of obesity, type 2 diabetes and overweight patients with a weight-related health problem. Belviq is manufactured by Arena Pharmaceuticals (NASDAQ: ARNA) and distributed in the USA by Eisai.

    Belviq is the first weight loss drug approved in 13 years by the FDA. Another drug approved bit later was Qsymia by Vivus (NASDAQ: VVUSmore »)

  • 2 Biotech Approval Outcomes That Might Affect You

    By Sherrie Stone - June 19, 2013 | Tickers: ARNA, MNKD, OREX, VVUS

    An FDA approval is the Holy Grail for biotechnology companies and their investors – but a successful launch is the most momentous in producing long-term gains. Thus, I am looking at two companies, both of which I expect to produce FDA approvals, but just one drug to create success in the open market.

    Possible approval, but not commercially successful

    MannKind Corporation (NASDAQ: MNKD) saw gains of more than 220% in 2013 more »

  • Consumer Reports Says "Exercise" Rather Than Take This Drug

    By Sherrie Stone - June 17, 2013 | Tickers: ARNA, VVUS

    The U.S. weight loss market is estimated at $61 billion, with the global weight management market expected to be $650 billion by 2015. Yet, despite this size, FDA approved weight loss products can't catch a break. Let's look at the latest blow to the industry and decide whether or not upside is present.

    The importance of Consumer Reports

    If you ponder the impact of Consumer Reports, just more »

  • An Obesity Drug Stock to Fatten your Portfolio?

    By Chris Lau - June 10, 2013 | Tickers: ARNA, VVUS

    Arena Pharmaceuticals (NASDAQ: ARNA) shares fell after the company announced the June 11 U.S. release of its obesity drug BELVIQ -- but that's not necessarily a bad thing. Over the previous week, investors had bid the drugmaker's shares above $9 in anticipation of the news; when it came, they sold. But with BELVIQ headed to shelves soon, there are a number of reasons why investors still expect good more »

  • Sarissa's Stake in VIVUS Points to Renewed Interest in the Company

    By Mike Thiessen - June 6, 2013 | Tickers: LLY, GSK, VVUS

    Noted hedge fund Sarissa Capital Management recently disclosed a stake of nearly 2% in promising biotechnology firm VIVUS (NASDAQ: VVUS). Although it had been widely anticipated by keen-eyed market observers, this event nevertheless highlighted the renewed interest in VIVUS' long-term prospects.

    Like many small biotech firms that focus on developing and marketing experimental or advanced drugs, VIVUS has had a volatile run over the past few years. After several quarters more »

  • Pfizer's Big Chance

    By Terry Chrisomalis - June 6, 2013 | Tickers: LLY, GSK, PFE, VVUS

    When we think of big pharma companies, the company we think about constantly is Pfizer (NYSE: PFE), especially as the company recently announced it will start selling Viagra online. This is a bold move, and I think that Pfizer has the financial backing to make it work. 

    There are other problems that Pfizer has to deal with here, like counterfeit pills from online pharmacies. Pfizer knows that this problem will more »

  • Why This Obesity Drug Is the Sector's Best Bet

    By Mohsin Saeed - May 24, 2013 | Tickers: ARNA, OREX, VVUS

    Editor's Note: The original article incorrectly stated Schedule IV drugs are the second-most-restrictive. This version has been corrected and Motley Fool apologizes for the oversight.

    The obesity drug space is becoming increasingly complex and hard to predict. After months of waiting patiently, Arena Pharmaceuticals (NASDAQ: ARNA) finally got a DEA schedule for its star drug Belviq in May, which could clear up the primary obstacle to Belviq’s availability more »

  • Arena's Marketing Partner Eisai Projects Sales To 4 Million Obese Patients By 2016

    By Joseph Dedvukaj - May 17, 2013 | Tickers: ARNA, VVUS

    Arena (Nasdaq: ARNA) and Eisai have an accurate picture of the potential value of Belviq by doing early stage market research. Eisai is in the top 25 largest pharmaceutical companies in the world. Eisai is a successful leading pharmaceutical company by both demonstrating an understanding of the importance of marketing and cleverly integrating it with the science. In accordance with the marketing agreement between the two companies, Eisai did the more »

  • Page 1 of 7